Background: Aminoglycoside G418 is commonly used to generate stable replicons for RNA viruses, such as hepatitis C virus, West Nile virus, and bovine viral diarrhoea virus (BVDV). This precludes testing G418's own antiviral activities against those viruses. Here, we report antiviral activity of G418 against BVDV. Methods: Cell viability and virus yield reduction assays were used to investigate antiviral effects of G418 against BVDV. The expression of viral proteins and RNA were determined by western blot and real-time quantitive PCR, respectively. Results: We demonstrated that G418 (50% cytotoxicity concentration of 400 µg/ml) improved cell viability of Madin-Darby bovine kidney cells infected with a cytopathic strain of BVDV (NADL) in a dose-dependent manner with 50% effective concentration of 4 µg/ml. The HCV RNA replicons, equipped with a neomycin resistance gene, allowed for the screening and identifications of new inhibitors of HCV intracellular replication. However, because replicons do not undergo a complete replication cycle, drug-screening programmes and mechanism of action studies based solely on these assays will not identify compounds targeting either early (virion attachment, entry and uncoating) or late (virion assembly and egress) stages of the viral replication cycle. In addition, it is possible that drugs that negatively affect neomycin resistance will also inhibit viral replication of HCV RNA replicons without affecting any of the viral mechanisms, creating a necessity to generate new screens to avoid this potential problem. Thus, aminoglycosides, such as neomycin analogues, which are potential antivirals, can never be used in an HCV replicon system to assess their antiviral potential.Bovine viral diarrhoea virus (BVDV) is commonly used as a surrogate model for HCV infection. BVDV is a cytoplasmic positive sense RNA virus that belongs to the Flaviviridae family [3]. BVDV is known to cause severe lesions in the gastrointestinal tract and death in affected animals [4,5]. Two biotypes, cytopathic (cpB-VDV) and non-cytopathic (ncpBVDV), can be isolated from infected animals [6]. However, only cpBVDV induces cytopathology in sensitive cell types, such as Madin-Darby bovine kidney (MDBK) cells.BVDV shares a similar structural organization with HCV [7]. Like HCV, BVDV may use the low-density lipoprotein receptor to enter cells, uses a functionally similar internal ribosome entry site (IRES) for translation, uses an NS4A cofactor with its homologous NS3 protease, has a similar NS3 helicase/NTPase, has a